Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT04329949 · RELIANT Phase 3Terminated
- Lead sponsor
- Corcept Therapeutics (Industry)
- Enrollment
- 43 (actual)
- Start date
- 30 Jun 2020
- Primary completion
- 23 Aug 2021 (actual)
- Study completion
- 25 Mar 2022
- Last update posted
- 18 Nov 2023
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Relacorilant, 100 mg and 25 mg Drug
- Nab-paclitaxel Drug
Conditions and primary outcome
- Metastatic Pancreatic Ductal Adenocarcinoma
Primary outcome
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Baseline and up to 32 weeks)
Posted results on ClinicalTrials.gov
Source: ClinicalTrials.gov results for NCT04329949 (opens in a new tab)· Licence: public-domain
First posted · Last update posted · Imported from ClinicalTrials.gov download 2026-10-25
Primary outcomes with a statistical analysis
No primary outcome with a statistical analysis is posted for this study.
Serious adverse events
Time frame: Up to 30 days after the last dose of study treatment (up to 73 weeks)
| Group | Affected | At risk |
|---|---|---|
| Relacorilant With Nab-paclitaxel | 23 | 43 |
Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT04329949.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04329949 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.